Dr. Lal Pathlabs Ltd (NSE: LALPATHLAB, BSE: 539524) is a Gurugram, Haryana-based company in the Medical Diagnostic Centres industry. With a market capitalisation of ₹33,934 Cr, it ranks #259 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 18 in Medical Diagnostic Centres. At ₹1,983.30 (as of 16 Nov 2026), the share price is 4.6% below its 52-week high of ₹2,079.00 and 55.8% above its 52-week low of ₹1,272.60. The share price is up 28.7% over one year and up 1.2% over three months.
| Current Price | ₹1,983.30 |
|---|---|
| Market Cap | ₹33,934 Cr |
| NSE Symbol | LALPATHLAB |
| BSE Code | 539524 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Services > Medical Diagnostic Centres |
| P/E Ratio | 66.4 |
| Return on Equity | 21.48% |
| Return on Assets | 13.34% |
| 52-Week Range | ₹1,272.60 – ₹2,079.00 |
| 1-Year Price Change | +28.7% |
| 3-Month Price Change | +1.2% |
| Beta (1Y) | 0.55 |
| Dividend Yield | 1.00% |
| Headquarters | Gurugram, Haryana |
| Website | www.lalpathlabs.com |
| Revenue | ₹874 Cr |
|---|---|
| Net Profit | ₹194 Cr |
| Net Margin | 22.2% |
| EPS (Basic) | ₹11.51 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Dr. Lal Pathlabs Ltd reported revenue of ₹874 Cr in Q2 FY27, up 19.6% from ₹731 Cr in Q2 FY26 and up 9.6% from ₹798 Cr in Q1 FY27. It posted a net profit of ₹194 Cr for the quarter, against a net profit of ₹152 Cr in Q2 FY26 (up 27.4%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹603 Cr (Q4 FY25) to ₹874 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹874 Cr | ₹194 Cr | 22.2% |
| Q1 FY27 | ₹798 Cr | ₹171 Cr | 21.4% |
| Q4 FY26 | ₹703 Cr | ₹132 Cr | 18.8% |
| Q3 FY26 | ₹660 Cr | ₹91 Cr | 13.9% |
| Q2 FY26 | ₹731 Cr | ₹152 Cr | 20.8% |
| Q1 FY26 | ₹670 Cr | ₹134 Cr | 20.0% |
| Q4 FY25 | ₹603 Cr | ₹156 Cr | 25.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 52.93% of Dr. Lal Pathlabs Ltd's shares as of Sept 2026, against 53.21% in Sept 2025 (−0.28 percentage points). Delivery averaged 58.5% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.
1. Running Laboratories-This segment engages in running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations.
1. Running Laboratories-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Dr. Lal Pathlabs Ltd | ₹33,934 Cr | 66.4 | 21.48% | ₹874 Cr | +28.7% |
| Vijaya Diagnostic Centre Limited | ₹14,665 Cr | 84.3 | 19.70% | ₹255 Cr | +38.5% |
| Metropolis Healthcare Limited | ₹11,952 Cr | 61.5 | 13.37% | ₹497 Cr | +14.9% |
| Throcare Technologies Ltd | ₹7,764 Cr | 47.6 | 28.74% | ₹271 Cr | +7.5% |
| SURAKSHA DIAGNOSTIC LIMITED | ₹1,856 Cr | 55.4 | 13.84% | ₹99 Cr | +6.9% |
| Krsnaa Diagnostics Ltd | ₹1,625 Cr | 16.8 | 10.89% | ₹271 Cr | -27.0% |
| Gaudium IVF and Women Health Limited | ₹803 Cr | 27.4 | 16.08% | ₹37 Cr | — |
| Chandan Healthcare Limited | ₹582 Cr | 21.9 | 18.43% | ₹81 Cr | — |
| Aspira Pathlab & Diagnostics Ltd | ₹127 Cr | 2,360 | — | — | +115.2% |
Listed by market capitalisation. Ratios are shown for context only.
Dr. Lal Pathlabs Ltd is trading at ₹1,983.30, with a market capitalisation of ₹33,934 Cr.
Dr. Lal Pathlabs Ltd operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Services > Medical Diagnostic Centres).
Dr. Lal Pathlabs Ltd has a P/E of 66.4 and a return on equity of 21.48%.
Dr. Lal Pathlabs Ltd is listed on the NSE under the symbol LALPATHLAB and on the BSE under the scrip code 539524.
Dr. Lal Pathlabs Ltd's share price is up 28.7% over one year and up 1.2% over three months. Its 52-week range is ₹1,272.60 to ₹2,079.00.
In Q2 FY27, Dr. Lal Pathlabs Ltd reported revenue of ₹874 Cr and net profit of ₹194 Cr, with basic EPS of ₹11.51 (consolidated, parsed from the company's exchange filing).
Dr. Lal Pathlabs Ltd reported revenue of ₹874 Cr in Q2 FY27, up 19.6% from ₹731 Cr in Q2 FY26 and up 9.6% from ₹798 Cr in Q1 FY27.
Promoters held 52.93% of Dr. Lal Pathlabs Ltd's shares as of Sept 2026, against 53.21% in Sept 2025 (−0.28 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.